Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease

NCT00206674 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

286

Enrollment

INDUSTRY

Sponsor class

Conditions

Crohn Disease

Interventions

DRUG: Sargramostim (Leukine)
DRUG: Placebo

Sponsor

Genzyme, a Sanofi Company